Related Experiment Videos
Antiangiogenic and antivascular therapy for cancer
1Mario Negri Institute for Pharmacological Research, Bergamo, Italy. taraboletti@marionegri.it
Abstract:
The great interest in the potential antineoplastic effect of targeting tumor-associated blood vessels has generated an expanding armamentarium of therapeutic tools that include antiangiogenic compounds, aimed at preventing the formation of vessels, and antivascular compounds, targeted to the existing tumor vasculature. Following promising preclinical studies, antiangiogenic drugs have rapidly gained access to clinical trials.
Insights
Targeting tumor blood vessels offers new cancer treatments. Antiangiogenic drugs prevent new vessel growth, while antivascular compounds attack existing ones, showing promise in clinical trials.
Area of Science:
- Oncology
- Vascular Biology
- Drug Development
Background:
- Tumor-associated blood vessels are crucial for cancer growth and metastasis.
- Targeting tumor vasculature presents a promising strategy for cancer therapy.
- Therapeutic approaches include antiangiogenic and antivascular compounds.
Purpose of the Study:
- To review the therapeutic strategies targeting tumor-associated blood vessels.
- To highlight the development and clinical application of antiangiogenic and antivascular compounds.
Main Methods:
- Literature review of preclinical and clinical studies.
- Analysis of therapeutic mechanisms of antiangiogenic and antivascular agents.
Main Results:
- Antiangiogenic compounds aim to inhibit the formation of new tumor blood vessels.
- Antivascular compounds target and damage the existing vasculature within tumors.
- Promising preclinical data has led to the advancement of antiangiogenic drugs into clinical trials.
Conclusions:
- Targeting tumor vasculature is a significant area of cancer research.
- Both antiangiogenic and antivascular strategies offer potential for cancer treatment.
- Clinical translation of these therapies is actively ongoing.